No data to show
XNAS
RNTX
Market cap42mUSD
Jun 10, Last price
1.94USD
Name
Aileron Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
44.23%
Rev. gr., 5y
%
Revenues
0k
Net income
-16m
L-41.76%
CFO
-20m
L-20.34%
Earnings
Aug 12, 2025
Profile
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 15,467 | 27,816 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (15,467) | (27,816) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (318) | ||||||||
Tax Rate | |||||||||
NOPAT | (15,467) | (27,498) | |||||||
Net income | (15,732) -41.76% | (27,011) 4.84% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 96 | 33 | |||||||
Long-term debt | 48 | 66 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,720 | ||||||||
Net debt | (17,169) | (21,143) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (19,808) | (24,865) | |||||||
CAPEX | |||||||||
Cash from investing activities | 16,196 | 26,459 | |||||||
Cash from financing activities | 15,794 | ||||||||
FCF | (15,376) | (27,328) | |||||||
| Balance | |||||||||
Cash | 17,313 | 21,242 | |||||||
Long term investments | |||||||||
Excess cash | 17,313 | 21,242 | |||||||
Stockholders' equity | (197,079) | (272,742) | |||||||
Invested Capital | 295,472 | 291,398 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 4,599 | 4,539 | |||||||
Price | 3.05 28.63% | 2.37 -78.95% | |||||||
Market cap | 14,020 30.32% | 10,758 -78.48% | |||||||
EV | 88,261 | (10,385) | |||||||
EBITDA | (15,348) | (27,647) | |||||||
EV/EBITDA | 0.38 | ||||||||
Interest | 318 | ||||||||
Interest/NOPBT | |||||||||